Sumita Ray Insider Profile
4 Followers
Sumita Ray, Chief Legal Compliance Officer, Corporate Secretary at Cue Biopharma, holds 118.55K shares in Cue Biopharma (Ticker: CUE), holds 105.00K shares in Calithera Bio (Ticker: CALA), holds 112.00 shares in Pharmacyclics (Ticker: PCYC).
Sumita Ray has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Sumita Ray holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Sumita Ray
Sumita Ray's Trading History
Cue Biopharma
Aug 17, 2026
Chief Legal Compliance Officer, Corporate Secretary
Uninformative Buy
291.13K
$3.32M
Pharmacyclics
Nov 05, 2013
―
Uninformative Buy
7.26K
―
Calithera Bio
Nov 09, 2021
―
Uninformative Buy
―
$2.63K
Biomea Fusion
―
Director
―
―
Instil Bio
―
Chief Legal and Admin Officer
―
―
Vaxxinity Inc
―
Chief Legal, Comp & Admin Off
―
―
List of latest transactions for each holding click on a transaction to see Sumita Ray's performance on stock
You May Also Like
Sumita Ray insider profile FAQ
What is the percentage of profitable transactions made by Sumita Ray?
The percentage of profitable transactions made by Sumita Ray is ―.
What is the average return per transaction made by Sumita Ray?
The average return per transaction made by Sumita Ray is ―.
What stocks does Sumita Ray hold?
Sumita Ray holds: CUE, PCYC, CALA, BMEA, TIL, VAXX stocks.
What was Sumita Ray’s latest transaction?
Sumita Ray latest transaction was an Uninformative Buy of $291.13K.
What was Sumita Ray's most profitable transaction?
Sumita Ray’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Sumita Ray's role in Cue Biopharma?
Sumita Ray's role in Cue Biopharma is Chief Legal Compliance Officer, Corporate Secretary.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.